| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3180161 | Actas Dermo-Sifiliográficas | 2014 | 7 Pages |
Abstract
Imiquimod may reduce the risk of subsequent BCC in patients treated for BCC and its effect could last for up to 2 years in local, regional and lymphatic cancerization fields. We believe that the cancerization field concept should be expanded to include not only the local area, but also the pertinent anatomic region and the regional lymphatic drainage area.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
J. Graells, R.M. Ojeda, A. GarcÃa-Cruz,